Abstract

 Thermotherapy can profoundly support the immune system to reduce viral replication. The objective of this literature review is to find supportive evidence in scientific literature to validate our previously published work on Thermotherapy using Infrared and negative ions Amethyst Bio mat on Diabetes, Cancer, Sleep Problems and Pain Management [100]..

Keywords: Thermotherapy; Immune System; Viral Replication

References

1. Papac RJ. “Spontaneous regression of cancer”. Cancer Treatment Reviews 22 (1996): 395-423.
2. Abel U. “Spontanremissionen und fieberhafte Erkrantungen”. In: Heim ME, Schwarz R, eds. “Spontanremissionen in der Onkologie” (1998): 68-75.
3. Hobohm U. “Fever and cancer”. Cancer Immunology, Immunotherapy 50 (2001): 391-396.
4. Bickels J. “Coley toxin: Historical perspective”. IMAJ 4 (2002): 471-472.
5. Coley-Nauts H and McLaren J. “Coley toxins-the first century. “Consensus On Hyperthermia for 1990s”. Advances in Experimental Medicine and Biology 267 (1990): 483-500.
6. Dickson JA and Shah SA. “Immunologic aspects of hyperthermia”. In: Storm FK, edition. “Hyperthermia in cancer therapy”. Boston, MS: G K Hall Publisher (1983): 487-543.
7. Dickson JA and Shah SA. “Hyperthermia and the immune response in cancer therapy”. Cancer Immunology, Immunotherapy 9 (1980): 1-10.
8. Dranoff G. “Cytokines in cancer pathogenesis and cancer therapy”. Nature Reviews Cancer. 4 (2004): 11-22.
9. Diefenbach A and Raulet DH. “The innate immune response to tumors and 1^st role in the induction of T-cell immunity”. Nature Reviews Immunology 188 (2002): 9-21.
10. Hilf N., et al. “The heat shock protein Gp96 links innate and specific immunity”. International Journal of Hyperthermia 18 (2002): 521-533.
11. Palucka K., et al. “Dendritic cells and tumour immunity”. Current Opinion in Oncology Endocrinology Metabolism Investigational Drugs 1 (1999): 282-290.
12. Bremes AJA and Parmiani G. “Immunology and immunotherapy of human cancer: Present concepts and clinical developments”. Critical Reviews in Oncology/Hematology 34 (2000): 1-25.
13. Ben-Efraim S. “One hundred years of cancer immunotherapy: A critical appraisal”. Tumor Biology 20 (1999): 1-24.
14. Davis ID., et al. “Rational approaches to human cancer immunotherapy”. Journal of Leukocyte Biology 73 (2003): 3-29.
15. Schirrmacher V., et al. “T-cell priming in bone marrow: The potential for long-lasting protective anti-tumor immunity”. Trends in Molecular Medicine 9 (2003): 526-534.
16. Lord EM and Frelinger JC. “Tumor immunotherapy: Cytokines and antigen presentation”. Cancer Immunology, Immunotherapy 46 (1998): 75-81.
17. Shurin MR., et al. “TH1/TH2 in cancer, transplantation and pregnancy”. Springer Seminars in Immunopathology 21 (1999): 339-359.
18. Nishimura T., et al. “Distinct role of antigen specific T Helper type 1 (Th1) and Th2 cells in tumor eradication In vivo”. Journal of Experimental Medicine 190 (1999): 617-627.
19. Titu LV., et al. “The role of CD8+ T cells in immune responses to colorectal cancer”. Cancer Immunology, Immunotherapy 51 (2002): 235-247.
20. Carlos TM. “Leukocyte recruitment at sites of tumour: Dissonant orchestration”. Journal of Leukocyte Biology 70 (2001): 171-184.
21. Fauriat C., et al. “Natural Killer Cell-Triggering receptors in patients with acute leukaemia”. Leukemia Lymphoma 44 (2003): 1683-1689.
22. Hoos A and Levey DL. “Vaccination with heat shock protein-peptide complexes: From basic science to clinical applications”. Expert Review of Vaccines 2 (2003): 369-379.
23. O' ByrneKJ., et al. “The relationship between angiogenesis and the immune response in carcinogenesis and progression of malignant disease”. European Journal of Cancer 36 (2000): 151-169.
24. Vaupel P., et al. “Blood flow, oxygen and nutrients supply, and metabolic microenvironment of human tumors, a review”. Cancer Research 49 (1989): 6449-6465.
25. Folkman J. “Tumour angiogenesis: Therapeutic implications”. The New England Journal of Medicine 285 (1971): 1182-1186.
26. Freitas I and Baronzio GF. “Tumour hypoxia, reoxygenation and oxygenation strategies: Possible role in photodynamic therapy”. The Journal of Photochemistry and Photobiology B: Biology 11 (1991): 3-30.
27. Berges G and Benjamin L. “Tumorigenesis and the angiogenic switch”. Nature Reviews Cancer 3 (2002): 401-410.
28. Griffioen AW and Molena G. “Angiogenesis: Potentials for pharmacological intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation”. Pharmacological Reviews 52 (2000): 238-268.
29. Griffioen AW., et al. “Angiogenesis modulates the tumour immune response”. International Journal of Experimental Pathology 79 (1998): 363-368.
30. Papetti M and Herman I. “Mechanisms of normal and tumour-derived angiogenesis”. The American Journal of Physiology: Cell Physiology 282 (2002): c947-c970.
31. Alexandroff AB., et al. “Sticky and smelly issues: Lessons on tumour cell and leukocyte trafficking, gene and immunotherapy of cancer”. British Journal of Cancer 77 (1998): 1806-1811.
32. Carlos TM and Harlan JM. “Leukocyte-endothelial adhesion molecules”. Blood 84 (1994): 2068.
33. Kitayama J., et al. “Suppressive effect of basic fibroblast growth factor on trans endothelial emigration of CD4(+) T-lymphocyte”. Cancer Research 54 (1994): 4729.
34. Barleon B., et al. “Migration of human monocytes in response to Vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1”. Blood 87 (1996): 3336-3343.
35. Borgstrom PG., et al. “Leukocyte adhesion in angiogenic blood vessels”. Journal of Clinical Investigation 99 (1997): 2246-2253.
36. Griffioen AW., et al. “Endothelial ICAM-1 expression is suppressed in human malignancies; role of angiogenic factors”. Cancer Research 56 (1996): 1111.
37. Mantovani A., et al. “Macrophage polarization: Tumor associated macrophages as a paradigm for polarized M2 mononuclear phagocytes”. Trends in Immunology 23 (2002): 549-555.
38. Hightower LE. “Heat shock, stress proteins, chaperones and proteotoxicity”. Cell 66 (1991): 191-197.
39. Smith DF., et al. “Molecular chaperones: Biology and prospects for pharmacological intervention”. Pharmacological Reviews 50 (1998): 494-513.
40. Manjili MH., et al. “Immunotherapy of cancer using Heat shock proteins”. Frontiers Bioscience 7 (2002): d43-d52.
41. Li GC., et al. “Heat shock proteins, thermotolerance and their relevance to clinical hyperthermia”. International Journal of Hyperthermia 11 (1995): 459-488.
42. Fortin A., et al. “Overexpression of the 27 KDA heat shock protein is associated with thermotolerance and chemoresistance but not with radioresistance”. Journal International Journal of Radiation Oncology Biology Physics 46 (2000): 1259-1266.
43. Wallin RPA., et al. “Heat shock proteins as activators of the innate immune system”. Trends in Immunology 23 (2002): 130-135.
44. Przepiorka D and Srivastava PK. “Heat shock protein-peptide complexes as immunotherapy for human cancer”. Molecular Medicine Today 11 (1998): 478-484.
45. Manjili MH., et al. “Cancer immunotherapy: Stress proteins and hyperthermia”. International Journal of Hyperthermia 18 (2002): 506-520.
46. Wells A and MalKovsky M. “Heat shock proteins, tumor immunogenicity and antigen presentation: An integrated view”. Immunology Today 21 (2001): 129-132.
47. Milani Y., et al. “Heat shock protein 70 in antigen presentation and immune stimulation”. International Journal of Hyperthermia 18 (2002): 563-575.
48. Flohe SB., et al. “Human heat shock protein 60 induces maturation of dendritic cells versus a TH1-promoting phenotype”. Journal of Immunology 170 (2003): 2340-2348.
49. Liu B., et al. “Overcoming immune tolerance to cancer by heat shock protein vaccines”. Molecular Cancer Therapeutics 1 (2002): 1147-1151.
50. Tamura Y., et al. “Immunotherapy of tumors with autologous tumor - derived heat shock protein preparations”. Science 269 (1995): 117-120.
51. Srivastava P. “Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens”. Methods 12 (1997): 165-171.
52. Basu S., et al. “Necrotic not apoptotic cell death release heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kB pathway”. International Immunology 12 (2000): 1539-1546.
53. Feng H., et al. “Stressed apoptotic tumor cells express heat shock proteins and elicit tumor specific immunity”. Blood 197 (2001): 3505-3512.
54. “Horizons in Cancer Therapeutics”. From Bench to Bedsides (2001).
55. Rosenberg SA. “Progress in the development of immunotherapy for the treatment of patients with cancer”. Journal of Internal Medicine 250 (2001): 462-475.
56. Sahin U., et al. “Serological identification of human tumor antigens”. Current Opinion in Immunology 9 (1997): 709-716.
57. Bitton RJ., et al. “Cancer Vaccines: An update with special focuses on gangliosides antigens (Review) ”. Oncology Reports 9 (2002): 267-276.
58. Ockert D., et al. “Advances in cancer immunity”. Immunology Today 20 (1999): 63-65.
59. Espinoza-Delgado I “Cancer vaccine”. The Oncologist 3 (2002): s20-s33
60. Ribas A., et al. “Current development in cancer vaccines and cellular immunotherapy”. Journal of Clinical Oncology 21 (2003): 2415-2432.
61. Osanto S. “Vaccine trials for the clinician: Prospects for tumor antigens”. The Oncologist 2 (1997): 284-299.
62. Parmiani G., et al. “Vaccination of patients with solid tumours”. Annals of Oncology 14 (2003): 817-824.
63. Fernandez NC., et al. “Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate antitumor immune response”. Nature Medicine 5 (1999): 405-411.
64. Celluzzi CM., et al. “Peptide pulsed dendritic Cells induce antigen - specific CTL-mediated protective antitumor activity”. Journal of Experimental Medicine 183 (1996): 283-287.
65. Ribas A., et al. “Cancer immunotherapy using gene- modified dendritic cells”. Current Gene Therapy 2 (2002): 57-78.
66. Weber J and Fong L. “Clinical trials of Dendritic Cells in cancer In: Lotze M, Thomson AW, eds.“Dendritic Cells”San Diego, San Francisco: Academic Press (2001): 561-571.
67. Haupt K., et al. “The potential of DNA vaccination against tumour-associated antigens for antitumor therapy”. Bulletin of Experimental Biology and Medicine 227 (2002): 227-237.
68. Pawelec G., et al. “Cells and Cytokines in immunotherapy and gene therapy of cancer”. Critical Reviews in Oncogenesis 10 (1999): 83-127.
69. Baar J. “Clinical applications of dendritic cell cancer vaccines”. The Oncologist 4 (1999): 140-144.
70. Gabrilovich DI., et al. “Production of vascular endothelial factor by tumour inhibits the functional maturation of dendritic cells”. Nature Medicine 2 (1996): 1096-1103.
71. Yamaguchi Y., et al. “Contrasting effects of TGF-β1 and TNF-α on the development og dendritic cells from progenitors in mouse bone marrow”. Stem Cells 15 (1997): 144-153.
72. Sharma S., et al. “Tumor cycloxygenase 2 -dependent suppression of dendritic cell function”. Clin Cancer Res. 9 (2003): 961-968.
73. Romano G. “Gene transfer in experimental medecine”. Drugs and Therapy Perspectives 16 (2003): 267-276.
74. Peng K-W. “Strategies for targeting therapeutic gene delivery”. Molecular Medicine Today 5 (1999): 448-453.
75. Romano G., et al. “Gene transfer technology in therapy. Current applications and future goals”. Stem Cells 17 (1999): 191-202.
76. Navarro JG., et al. “Gene therapy of cancer”. European Journal of Cancer 35 (1999): 867-885.
77. Kufe DW., et al. “Principles of gene therapy”. In: Bast, Kufe, Pollock, Weichselbaum, Holland, Frei, eds. “Cancer Medicine”. Hamilton, Ontario: BC Decker Publisher (2000): 876-890.
78. Rochlitz CF. “Gene therapy of cancer”. Swiss Medical Weekly 131 (2001): 4-9.
79. Farzaneh F., et al. “Gene therapy of cancer”. Immunology Today 19 (1998): 294-296.
80. Clark RP and Hersh EM. “Cationic lipid-mediated gene transfer: Current concepts”. Current Opinion in Molecular Therapeutics 1 (1999): 158-76.
81. Davis ME. “Non -viral gene delivery systems”. Current Opinion in Biotechnology 13 (2002): 128-131.
82. Maurer N., et al. “Development in liposomal drug delivery systems”. Expert Opinion on Biological Therapy 1 (2001): 923-947.
83. Boulikas T. “Liposome DNA delivery and uptake by cells”. Oncology Reports 3 (1996): 989-005.
84. Koshkina NV., et al. “Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: Optimisation of pulmonary delivery and retention”. Molecular Therapy 8 (2003): 249-254.
85. Densmore CL. “The reemergence of aerosol gene delivery: A viable approach to lung cancer therapy”. Current Cancer Drug Targets 3 (2003): 273-284.
86. Singh-Jasuja H., et al. “The heat shock protein gp96: A receptor-targeted cross-priming carrier and activator of dendritic cells”. Cell Stress Chaperones5 (2000): 462-470.
87. Mazzaferro V., et al. “Vaccination with autologous derived Heat shock protein gp96 after liver resection for metastatic colorectal cancer”. Clinical Cancer Research 9 (2003): 3235-3245.
88. Saper CB and Breder CD. “The neurologic basis of fever”. The New England Journal of Medicine 30 (1994): 1880-1886.
89. Dinarello CA. “Cytokines as endogenous pyrogens”. The Journal of Infectious Diseases2 (1999): s294-s304.
90. Netea MG and Kulberg BJ. “Circulating cytokines as mediators of fever”. The Journal of Infectious Diseases2 (1999): s178-s184.
91. Blatteis CM and Sehic E. “Cytokines and fever”. Annals of the New York Academy of Sciences 840 (1998): 608-618.
92. Ahlers O., et al. “Induced hyperthermia causes significant changes in lymphocytes”. Critical Care 1 (1998): 002.
93. Jampel HD., et al. “Fever and immuneregulation”. Journal of Experimental Medicine 157 (1983): 1229-1238.
94. Hanson DF. “Fever, temperature, and the immune response”. Annals of the New York Academy of Sciences 813 (1997): 453-464.
95. Bell JF and Moore GF. “Effects of high ambient temperature on various stage of rabies virus infection in mice”. Infection and Immunity 10 (1974): 510-515.
96. Hasday JD. “The influence of temperature on host defenses”. In: Mackowiak PA, edition. “Fever: Basic mechanisms and management”. 2^nd edition Philadelphia: Lippincott-Raven Publishers (1977): 177-196.
97. Roberts NJ. “Impact of temperature elevation on immunologic defences”. RID 13 (1991): 452-472.
98. Lederman HM., et al. “Interleukin-1 driven secretion of interleukin-2 is highly temperature dependent”. Journal of Immunology 138 (1987): 3808-3811.
99. Gautherie M. “Hyperthermia and the immune system”. In: Gautherie M, edition. “Whole Body Hyperthermia: Biological and clinical aspects”. Berlin-Heidelberg-New York: Springer-Verlag 19926-19915.
100. Grant George F. “Evaluating Thermotherapy using The Amethyst Bio belt and the Infra Red Negative Ions Amethyst Bio Mat in 12 subjects to reduce fat, pain and stress over 3 months”. International Journal of Aesthetic and Anti-Ageing Medicine (2013).

Citation

Citation: George Grant and Jay P Vanden Heuvel. “Literature Review on the Benefits of Thermotherapy to Boost Immune System and Reduce Viral Replication".Acta Scientific Neurology 3.6 (2020): 37-46.

Copyright

Copyright: © 2020 George Grant and Jay P Vanden Heuvel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.